Cayman Islands vs Saint Barthélemy: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Cayman Islands
0.2%
in 2024
Saint Barthélemy
0.2%
in 2024
Cayman Islands rank
98th
Saint Barthélemy rank
98th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Cayman Islands
- Saint Barthélemy
How they compare
Cayman Islands currently reports 0.2% against 0.2% in Saint Barthélemy, a difference of 0.0%.
Across all 10 years both countries report, Saint Barthélemy has been ahead every year.
Cayman Islands ranks 98th and Saint Barthélemy ranks 98th of 246 countries.
Head to head by decade
| Decade | Cayman Islands | Saint Barthélemy | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.3% | 0.3% | 0.0% | — |
| 2020s | 0.2% | 0.2% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Cayman Islands or Saint Barthélemy?
- Cayman Islands, at 0.2% against 0.2% in Saint Barthélemy as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Cayman Islands and Saint Barthélemy?
- 0.0%, with Cayman Islands ahead.
- How many years of comparable data are there for Cayman Islands and Saint Barthélemy?
- 10 years are reported by both, from 2015 to 2024.
- How do Cayman Islands and Saint Barthélemy rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Cayman Islands ranks 98th and Saint Barthélemy ranks 98th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.